Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Al Saleh, Sanaa ^a   Al Mulla, Fahd ^a   Luqmani, Yunus A ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; SMALL INTERFERING RNA; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOSKELETON; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MORPHOLOGY; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; BREAST TUMOR; CANCER INVASION; CELL MOTION; CELL SHAPE; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SHAPE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICROARRAY ANALYSIS; NEOPLASM INVASIVENESS; RECEPTORS, ESTROGEN; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 79959344615     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020610     Document Type: Article

References (62)

1. Ali S, Coombes RC, (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev 2: 101-112.
2. Howell A, Bundred NJ, Cuzick J, Allred DC, Clarke R, (2008) Response and resistanceto the endocrine prevention of breast cancer. Adv Exp Med Biol 617: 201-211.
3. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, et al. (2005) Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Related Cancer 12: 721-747.
4. Schiff R, Massarweh S, Shou J, Bharwani L, Mohsin SK, et al. (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clini Cancer Res 10: 331-336S.
5. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, et al. (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283: 29897-29903.
6. Musgrove EA, Sutherland RL, (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev 9: 631-643.
7. Arpino G, Wiechmann L, Osborne CK, Schiff R, (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29: 217-233.
8. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson A, Nicholson RI, et al. (2008) Regulation of erbB2 by estrogen receptor-PAX2 determines response to tamoxifen. Nature 456: 663-666.
9. Yan W, Cao QJ, Arenas RB, Bentley B, Shao R, (2010) GATA3 Inhibits Breast Cancer Metastasis through theReversal of Epithelial-Mesenchymal Transition. J Biol Chem 285: 14042-14051.
10. Gilles C, Thompson EW, (1996) The epithelial to mesenchymal transition and metastatic progression in carcinoma. Breast J 2: 83-96.
11. Berx G, Raspe E, Christofori G, Thiery JP, Sleeman JP, (2007) Pre-EMTing metastasis: recapitulation of morphogenetic processes in cancer. Clin Exp Metas 24: 587-597.
12. Tse JC, Kalluri R, (2007) Mechanisms of metastasis: epithelial-to mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101: 816-829.
13. Sphyrus N, Mani SA, (2009) The importance of the epithelial-mesenchymal transition in breast cancer. Curr Breast Cancer Rep 1: 229-237.
14. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, et al. (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68: 989-997.
15. Berx G, van Roy F, (2001) The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3: 289-293.
16. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR, (2008) Cadherin switching. J Cell Sci 121: 727-732.
17. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, et al. (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68: 3645-3653.
18. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, et al. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumour metastasis. Cell 117: 927-939.
19. Sarrio D, Palacios J, Hergueta-Redondo M, Gómez-López G, Cano A, et al. (2009) Functional characterization of E- and P-cadherin in invasive breast cancer cells. BMC Cancer 9: 74-76.
20. Kim S, Kang HY, Nam EH, Choi MS, Zhao XF, et al. (2010) TMPRSS4 induces invasion and epithelial-mesenchymal transition through up-regulation of integrin α5 and its signalling pathways. Carcinogenesis 31: 597-606.
21. Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, et al. (2010) Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci 107: 124-1129.
22. Kokkinos MA, Wafai R, Wong MK, Newgreen DF, Thompson EW, et al. (2007) Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tiss Organs 185: 191-203.
23. Dandachi N, Hauser-Kronberger C, More E, Wiesener B, Hacker GW, et al. (2001) Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and onco-proteins. J Pathol 193: 181-189.
24. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton CM, et al. (2009) Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci 106: 3913-3918.
25. Linger RM, Keating AK, Earp HS, Graham DK, (2008) TAM receptor tyrosine kinases: biologic functions, signalling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100: 35-83.
26. Care A, Felicetti F, Meccia E, Bottero L, Parenza M, et al. (2001) HOXB7: a key factor for tumor-associated angiogenic switch. Cancer Res 61: 6532-6539.
27. Care A, Silvani A, Meccia E, Mattia G, Peschle C, et al. (1998) Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence. Oncogene 16: 3285-3289.
28. Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, et al. (2010) HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci 107: 1100-1105.
29. Orlichenko LS, Radisky DC, (2008) Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumour development. Clin Exp Metastasis 25: 593-600.
30. Luqmani YA, Al Azmi A, Al Bader M, Abraham G, El Zawahri M, (2009) Modification of gene expression induced by siRNA targeting of estrogen receptor in MCF7 human breast cancer cells. Int J Oncol 34: 231-242.
31. Thompson EW, Newgreen DF, Tarin D, (2005) Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 65: 5991-5995.
32. Kun Y, How LC, Hoon TP, Bajic VB, Lam TS, et al. (2003) Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor. Hum Mol Genet 12: 3245-3258.
33. Huang H, Horng JT, Lee C, Liu B, (2003) ProSplicer: a database of putative alternative splicing information derived from protein, mRNA and expressed sequence tag sequence data. Genome Biology 4: R29.
34. Lonning PE, Sorlie T, Perou CM, Brown PO, Botstein D, et al. (2001) Microarrays in primary breast cancer-lessons from chemotherapy studies. Endocr Relat Cancer 8: 259-263.
35. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adélaïde J, et al. (2006) Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 6: 2273-2357.
36. Landemaine T, Jackson A, Bellahcène A, Rucci N, Sin S, et al. (2008) Six-Gene Signature Predicting Breast Cancer Lung Metastasis. Cancer Res 68: 6092-6101.
37. Işeri OD, Kars MD, Arpaci F, Atala C, Pak I, et al. (2010) Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern doi:10.1016/j.biopha.2010.10.004.
38. Al-Azmi A, (2006) Estrogen receptor gene silencing in breast cancer cells using siRNA. MSc thesis, Kuwait University.
39. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: 2002-2007.
40. Al-Mulla F, Bitar MS, Taqi Z, Rath O, Kolch W, (2011) RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. Mol Biosyst DOI:10.1039/C0MB00208A.
41. Wiggins HL, Rappoport J, (2010) An agarose spot assay for chemotactic invasion. Biotechniques 48: 121-124.
42. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z, (2009) GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 10: 48.
43. van den Abbeele A, De Corte V, Van Impe K, Bruyneel E, Boucherie C, et al. (2007) Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro. Cancer Lett 255: 57-70.
44. Hazan RB, Qiao R, Keren R, Badano I, Suyama K, (2004) Cadherin switch in tumor progression. Ann N Y Acad Sci 1014: 155-163.
45. Navarro A, nand-Apte B, Parat MO, (2004) A role for caveolae in cell migration. FASEB J 18: 1801-1811.
46. Nicholson IR, Hutcheson D, Britton JM, Knowlden HE, Jones ME, et al. (2005) Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol 93: 257-262.
47. Knowlden JM, Hutcheson IR, Barrow D, Gee JMW, Nicholson RI, (2005) Insulin-Like Growth Factor-I Receptor Signaling in Tamoxifen-Resistant Breast Cancer: A Supporting Role to the Epidermal Growth Factor Receptor Endocrinology 146: 4609-4618.
48. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, et al. (2010) FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer. Cancer Res 70: 2085-2094.
49. Choi J, Park SY, Joo CK, (2007) Transforming growth factor-beta1 represses E-cadherin production via SNAIL2 expression in lens epithelial cells. Invest Ophthalmol Vis Sci 48 (6): 2708-18.
50. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, et al. (2009) A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol 11: 943-950.
51. Zavadil J, Bottinger EP, (2005) TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24: 5764-5774.
52. Deng B, Yang X, Liu J, He F, Zhu Z, et al. (2010) Focal adhesion kinase mediates TGF-beta1-induced renal tubular epithelial-to-mesenchymal transition in vitro. Mol Cell Biochem 340: 21-29.
53. de Graauw M, van Miltenburg MH, Schmidt MK, Pont C, Lalai R, et al. (2010) Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. Proc Natl Acad Sci USA 107: 6340-6345.
54. Bindels S, Mestdagt M, Vandewalle C, Jacobs N, Volders L, et al. (2006) Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene 25: 4975-4985.
55. Hollier BG, Evans K, Mani SA, (2009) The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mamm Gland Biol Neoplasia 14: 29-43.
56. Polyak K, Weinberg RA, (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273.
57. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, et al. (2006) CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8: R59.
58. Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, et al. (2003) MTA3, a Mi-2/NuRD Complex Subunit, Regulates an Invasive Growth Pathway in Breast Cancer. Cell 113: 207-219.
59. Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX, et al. (2008) ERα suppresses SNAIL2 expression directly by transcriptional repression. Biochem J 416: 179-187.
60. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, et al. (2007) Epithelial-Mesenchymal and Mesenchymal-Epithelial Transitions in Carcinoma Progression. J Cell Physiol.213: 374-383.
61. Sabbah M, Emami S, Redeuilh G, Julien S, Prévost G, et al. (2008) Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resistance Updates 11: 123-151.
62. Al Saleh S, Sharaf LH, Luqmani YA, (2011) Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition. Int J Oncol 38 (5): 1197-217.